Amy Heimberger
Northwestern University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amy Heimberger as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:08 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05879250 · WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaNorthwestern University · recruiting · Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 5 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Phase II Clinical Trial in Newly Diagnosed Glioblastoma Patients Treated with WP1066 and RadiationR01CA272639 · NCI · NORTHWESTERN UNIVERSITY · fiscal years 2023 to 2026 · $497,895 awarded in 2026Same name and institution; not confirmed by an ID
- STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY · fiscal years 2023 to 2026 · $343,601 awarded in 2026Same name and institution; not confirmed by an ID
- Modulation of Microglia and T Cell Interactions in Malignant GliomaR01CA120813 · NCI · NORTHWESTERN UNIVERSITY · fiscal years 2007 to 2025 · $287,999 awarded in 2025Same name and institution; not confirmed by an ID
- Stinging the Glioma Immune LandscapeR01NS120547 · NINDS · NORTHWESTERN UNIVERSITY · fiscal years 2020 to 2023 · $324,017 awarded in 2023Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA060553 · NCI · NORTHWESTERN UNIVERSITY · PI Aleksandar Zafirovski · fiscal years 2012 to 2026Named on NCT05879250
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 11:08 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- 650 citationsRCR 14.4
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.Neuro Oncol · 2015345 citationsRCR 10.5
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.Neuro Oncol · 2011295 citationsRCR 6.9
- An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.Mol Cancer Ther · 2009223 citationsRCR 4.9
- Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons.Neuro Oncol · 2021131 citationsRCR 8.0
- A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma.Neuro Oncol · 202198 citationsRCR 6.2
- A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.CNS Oncol · 202275 citationsRCR 5.6
- Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.Clin Cancer Res · 202046 citationsRCR 1.7
- Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.J Immunol Methods · 200838 citationsRCR 0.8